FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burde	n
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

10b5-1(c). See Instr	uction 10.							
1. Name and Address Oliviero James			2. Issuer Name and Ticker or Trading Symbol Checkpoint Therapeutics, Inc. [CKPT]		Relationship of Reporting Person(s) to Issuer leck all applicable) X Director 10% Owner			
(Last) 95 SAWYER RD,	(First) SUITE 110	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/30/2025	X	Director Officer (give title below) CEO, Presiden	Other (specify below)		
(Street) WALTHAM (City)	MA (State)	02453 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	Form filed by One Re	ng (Check Applicable Line) eporting Person nan One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, Transaction			4. Securities Acc Disposed Of (D)			Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)		(Instr. 4)
COMMON STOCK (RESTRICTED)	01/30/2025		A		1,500,000(1)	A	\$0	3,794,583(2)	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

-1	1. Title of	2.	3. Transaction	3A. Deemed	4.				6. Date Exercisable and		7. Title and Amount of		8. Price of	9. Number of	10.	11. Nature	ı
-1	Derivative	Conversion	Date	Execution Date,	Transaction		Derivative		Expiration Date		Securities Underlying		Derivative	derivative	Ownership	of Indirect	L
-1	Security (Instr. 3)	or Exercise	(Month/Day/Year)	if any	Code (Instr.		(Instr. Securities		(Month/Day/Year)		Derivative Security		Security	Securities	Form:	Beneficial	L
-1		Price of		(Month/Day/Year)	8)	8) Acquired (A)				(Instr. 3 and 4)		(Instr. 5)	Beneficially	Direct (D)	Ownership	L	
-1		Derivative			or Disposed of		or Disposed of						Owned	or Indirect	(Instr. 4)	L	
-1		Security			(D) (Instr. 3, 4		4				Following	(I) (Instr. 4)		L			
-1					and 5)		ind 5)					Reported			L		
-1													1	Transaction(s)			L
-1						l						Amount		(Instr. 4)			L
-1						l						or					1
-1						l			Date	Expiration		Number					1
1					Code	٧	(A)	(D)	Exercisable	Date	Title	of Shares					

Explanation of Responses:

- 1. The shares of restricted stock vest as follows: one-third on January 30, 2026, one-third on January 30, 2027, and January 30, 2028.
- 2. Includes shares of restricted common stock, which vest over various time periods.

/s/ James F. Oliviero, III 01/31/2025

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.